Publications by authors named "E G Griffin"
Background: Obesity is a risk factor for developing cancer but is also associated with improved outcomes after treatment with immune checkpoint inhibitors (ICIs), a phenomenon called the obesity paradox. To interrogate mechanisms of divergent immune responses in obese and non-obese patients, we examined the relationship among obesity status, clinical responses, and immune profiles from a diverse, pan-tumor cohort of patients treated with ICI-based therapy.
Methods: From June 2021 to March 2023, we prospectively collected serial peripheral blood samples from patients with advanced or metastatic solid tumors who received ICI as standard of care at Johns Hopkins.
Purpose: Intraprocedural complications during intracranial embolisation include thromboembolic vessel occlusion, catheter tip detachment and coil migration. Stentrievers and aspiration catheters are valuable devices for the management of these complications. We present our experience with the use of these devices.
View Article and Find Full Text PDFAnalysis of The 2024 ESC/EACTS Guidelines For The Management Of Atrial Fibrillation.
J Cardiothorac Vasc Anesth
November 2024
The 2024 European Society of Cardiology guidelines for atrial fibrillation (AF) emphasize a patient-centered approach to management, structured around the AF-CARE pathway: Comorbidity and risk factor management (C), Avoiding stroke and thromboembolism (A), Reducing symptoms through rate and rhythm control (R), and Evaluation and dynamic reassessment (E). This framework ensures that comorbidities such as hypertension, heart failure, diabetes, and obesity are effectively managed to prevent disease progression and improve outcomes. A key principle of the guidelines is shared decision making involving patients, families, caregivers, and healthcare teams to ensure individualized care that reflects patient preferences.
View Article and Find Full Text PDFArticle Synopsis
- Immune-related adverse events (irAEs) pose significant risks for patients receiving immune checkpoint inhibitors (ICIs), highlighting the need to identify patients at higher risk and develop strategies to manage these complications.
- An observational study involving 111 patients found that 40.5% experienced symptomatic irAEs, with higher rates linked to combination ICI therapy and pre-existing autoimmune disorders.
- Early increases in specific cytokines and T helper cell populations were associated with developing severe irAEs, indicating potential biomarkers for monitoring and targeting therapeutic interventions.